✦ LIBER ✦

Randomized Phase II Trial Comparing Exemestane to Tamoxifen for First-Line Hormonal Therapy of Postmenopausal Patients with Metastatic Breast Cancer

✍ Scribed by Kavita Maung; Joyce O'Shaughnessy

Book ID: 117794031
Publisher: CIG Media Group, LP.
Year: 2001
Tongue: English
Weight: 108 KB
Volume: 2
Category: Article
ISSN: 1526-8209
DOI: 10.1016/s1526-8209(11)70304-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Randomized trial or the selective aromat

Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer

✍ R. Peréz-Carrion; V. Alberola; F. Calabresi; R-Th. Michel; R. Santos; M. Fehling 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 298 KB

Multicenter phase II trial of neoadjuvan

Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone-sensitive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)

✍ H. Takei; Suemasu; K. Inoue; T. Saito; K. Okubo; J. Koh; K. Sato; H. Tsuda; M. K 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Multicenter phase II trial of neoadjuvan

Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)

✍ Hiroyuki Takei; Kimito Suemasu; Kenichi Inoue; Tsuyoshi Saito; Katsuhiko Okubo; 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 228 KB

365 Randomized trial between selective a

365 Randomized trial between selective aromatase inhibitor formestane (®lentaron) vs tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: Confirmation of bioequivalence in survival

✍ L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Michel; R. Santos 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views